[In vitro studies of PDR brachytherapy]

Area of Science:

• Radiobiology
• Radiation Oncology
• Cellular Kinetics

Background:

• Investigated radiobiological equivalence between continuous low dose rate (CLDR) irradiation and pulsed dose rate (PDR) superfractionation.
• Explored the potential of PDR brachytherapy to replace conventional CLDR brachytherapy.
• Hypothesized that superfractionation could achieve dose rate equivalency in vitro.

Purpose of the Study:

• To test the hypothesis that superfractionation can achieve low dose rate (LDR) equivalency.
• To evaluate the radiobiological effects of PDR irradiation compared to CLDR.
• To examine cell survival and cell cycle distribution under different fractionation schemes.

Main Methods:

• In vitro experiments using V79 cells (monolayer and spheroid) and HeLa cells.
• Simulated PDR brachytherapy fractionation in a dose rate gradient.
• Compared various superfractionation schedules (e.g., 40x0.47 Gy, 20x0.94 Gy) to CLDR reference curves over 20 hours.
• Utilized flow cytometry to assess cell survival and cell cycle distribution.

Main Results:

• V79 spheroids (slowly growing tumor model) showed CLDR equivalency with increasing fractionation.
• Rapidly growing V79 monolayer cells exhibited an inverse fractionation effect, with superfractionation being more effective than CLDR.
• This enhanced effect in V79 monolayers was linked to G2/M phase arrest.
• HeLa cells were insensitive to fractionation changes, showing CLDR equivalent curves for both superfractionation and hypofractionation.

Conclusions:

• The PDR fractionation scheme for CLDR equivalency is not universally applicable to all cell lines.
• Proliferation and dose rate-dependent cell cycle effects significantly influence irradiation outcomes.
• Pulsed irradiation may be more effective for rapidly growing tumors due to cell cycle modulation.